Bayer - Possible Settlement in Glyphosate Dispute Brings Momentum!

Business drivers: Bayer has suffered massively from billion-dollar compensation claims related to the glyphosate scandal in recent years, which has also left noticeable marks on the corporate results. In its core business, the company continues to benefit from robust prospects in the pharmaceutical segment, particularly with some blockbusters like the kidney medication Kerendia, which has recently performed solidly thanks to expanded approvals. Significant progress has also been made in the R&D pipeline, as the company showcased positive clinical...